High Dose D-serine In The Treatment Of Schizophrenia
| Effect |
Decrease |
| Trial Design |
Cohort |
| Trial Length |
2-4 Weeks |
| Number of Subjects |
42 |
| Gender |
Both Genders |
Notes for this study:
D-Serine at doses between 30-120mg/kg was dose-dependently effective in reducing all symptoms of schizophrenia, with 30mg/kg being ineffective on some (but not all) parameters. Improvements in symptoms appeared to correlate with blood D-serine concentrations
A Randomized, Double-blind, Placebo-controlled Comparison Study Of Sarcosine (N-methylglycine) And D-serine Add-on Treatment For Schizophrenia
| Effect |
None |
| Trial Design |
Double blind |
| Trial Length |
1-6 months |
| Number of Subjects |
60 |
| Gender |
Both Genders |
| Age Range |
30-44, 45-64 |
Notes for this study:
In 60 persons with schizophrenia given 2,000mg D-serine daily for 6 weeks, D-serine supplementation failed to outperform placebo on all measured parameters while the reference drug (sarcosine) was effective at the same dose.
D-serine Added To Antipsychotics For The Treatment Of Schizophrenia
| Effect |
Decrease |
| Trial Design |
Double blind |
| Trial Length |
1-6 months |
| Number of Subjects |
28 |
| Gender |
Both Genders |
| Age Range |
18-29, 30-44, 45-64 |
Notes for this study:
Supplementation of 30mg/kg D-serine to schizophrenic patients for 6 weeks was able to reduce all symptoms of schizophrenia, and serum concentrations of D-serine were able to predict the improvements seen in rating scales.
D-serine Efficacy As Add-on Pharmacotherapy To Risperidone And Olanzapine For Treatment-refractory Schizophrenia
| Effect |
Decrease |
| Trial Design |
Double blind |
| Trial Length |
1-6 months |
| Number of Subjects |
39 |
| Gender |
Both Genders |
| Age Range |
30-44, 45-64 |
Notes for this study:
30mg/kg of D-serine daily in addition to antipsychotic therapy (risperidone or olanzapine) was able to improve negative, positive, depressive, and cognitive scores over 6 weeks with the improvement on symptoms being 4.3-20.6% (95% CI of SAS rating scale), 19.8-57.7% (95% CI of AIMS), and 14 patients on D-serine noted over a 20% improvement on negative and positive symptoms while only 2 subjects on placebo did.
Sarcosine Or D-serine Add-on Treatment For Acute Exacerbation Of Schizophrenia: A Randomized, Double-blind, Placebo-controlled Study
| Effect |
None |
| Trial Design |
Double blind |
| Trial Length |
1-6 months |
| Number of Subjects |
65 |
| Gender |
Both Genders |
| Age Range |
30-44, 45-64 |
Notes for this study:
6 weeks supplementation of 2,000mg D-serine (compared to both placebo and an equal dose of sarcosine) has failed to outperform placebo when both were added to risperidone therapy.
A Multicenter, Add-on Randomized Controlled Trial Of Low-dose D-serine For Negative And Cognitive Symptoms Of Schizophrenia
| Effect |
None |
| Trial Design |
Double blind |
| Trial Length |
6+ Months |
| Number of Subjects |
195 |
| Gender |
Both Genders |
| Age Range |
18-29, 30-44, 45-64 |
Notes for this study:
In 195 persons with schizophrenia already on antipsychotic treatment, the addition of 2,000mg D-serine daily for 16 weeks failed to outperform placebo at controlling positive and negative symptoms of schizophrenia and failed to significantly affect cognition.
